Protective effects of saponin on a hypertension target organ in spontaneously hypertensive rats

Experimental and Therapeutic Medicine

Volumn 5, Issue 2, 2013, Pages 429-432

  Chen, Ming ^a,b   Long, Zijiang ^a   Wang, Yajuan ^a   Liu, Jinlin ^c   Pian, Hai ^a   Wang, Liang ^a   Chen, Zhiwu ^b  

^a ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c Anqing Medical and Pharmaceutical College   (China)

Author keywords

Hypertension; Renin angiotensin aldosterone system; Saponin

Indexed keywords

COLLAGEN TYPE 1; MESSENGER RNA; PLACEBO; RENIN; SAPONIN; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HYPERTENSION; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84871353252     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.856     Document Type: Article

References (17)

1. Delcayre C and Swynghedauw B: Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 34: 1577-1584, 2002.
2. Weber KT: Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96: 4065-4082, 1997.
3. Urata H, Nishimura H, Ganten D and Arakawa K: Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Blood Press Suppl 2: 22-28, 1996.
4. Olivetti G, Capasso JM, Sonnenblick EH and Anversa P: Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 67: 23-34, 1990.
5. Zannad F, Alla F, Dousset B, et al: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102: 2700-2706, 2000.
6. Bauersachs J and Fraccarollo D: Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure. Minerva Cardioangiol 51: 155-164, 2003.
7. Jorde UP, Vittorio T, Katz SD, et al: Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 106: 1055-1057, 2002.
8. McKelvie RS, Yusuf S, Pericak D, et al: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100: 1056-1064, 1999.
9. Kodavanti UP, Schladweiler MC, Ledbetter AD, et al: The spontaneously hypertensive rat as a model of human cardiovascular disease: evidence of exacerbated cardiopulmonary injury and oxidative stress from inhaled emission particulate matter. Toxicol Appl Pharmacol 164: 250-263, 2000.
10. Sagvolden T: Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 24: 31-39, 2000.
11. Singh VP, Le B, Bhat VB, et al: High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 293: H939-H948, 2007.
12. de Zeeuw D, Remuzzi G, Parving HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320, 2004.
13. Border WA and Noble NA: Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 31: 181-188, 1998.
14. Ichihara A, Hayashi M, Kaneshiro Y, et al: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J Clin Invest 114: 1128-1135, 2004.
15. Ichihara A, Suzuki F, Nakagawa T, et al: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 17: 1950-1961, 2006.
16. Burcklé CA, Jan Danser AH, Müller DN, et al: Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 47: 552-556, 2006.
17. Nguyen G, Delarue F, Burcklé C, et al: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002.